<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463330</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00140835</org_study_id>
    <nct_id>NCT03463330</nct_id>
  </id_info>
  <brief_title>Benefits of a Mild Body Exercise in Parkinson's Disease</brief_title>
  <official_title>Benefits of a Mild Body Exercise in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn the effects of two mild body exercises on quality of
      life, non-motor symptoms, anxiety, depression, fatigue, sleep quality, cognition, and
      executive function on people with Parkinson's Disease (PD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parkinson's Disease Sleep Scale (PDSS-2)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 60. The lower the score the better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ-39)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Measure of quality of life. This instrument has a total range of scores between 0 and 156. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Motor Symptom Questionnaire (NMSQuest)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 30. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Anxiety Scale (GAS-10)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 30. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale (GDS-15)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 15. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Fatigue Scale (PFS-16)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 16 and 90. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease-Cognitive Rating Scale (PD-CRS)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 134. The higher the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal Assessment Battery (FAB-18)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 18. The higher the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ten Point Clock Test (TPCT)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test parts A</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test parts B</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson Disease Rating Scale (UPDRS)</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>This instrument has a total range of scores between 0 and 199. The lower the score the better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1beta</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>Serum biomarker will be measured by Enzyme Linked Immuno-Sorbent Assay (ELISA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Qigong exercise</intervention_name>
    <description>The Qigong exercise is a series of mild exercise movements.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mild body exercise</intervention_name>
    <description>Participants will be taught of series of similar movements to the Qigong exercise.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic PD

          -  Currently taking levodopa with some improvement in motor symptoms, and on a stable
             dose for a minimum of 4 weeks prior to starting the study

          -  Hoehn &amp; Yahr stage I to III (mild to moderate PD)

        Exclusion Criteria:

          -  Mini Mental State Examination (MMSE) score &lt; 24

          -  Central neurological diseases other than PD or prior major head trauma with loss of
             consciousness, including other forms of parkinsonism, uncontrolled or significant
             cardiovascular diseases, orthopedic or medical problems that would interfere with gait

          -  Being primarily wheelchair bound

          -  Deep brain stimulation

          -  Expected change in PD medications over the course of the study

          -  Subjects with MRI contraindications such as pacemaker, aneurysm clips, artificial
             heart valves, metal fragments, foreign objects or claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanghee Moon</last_name>
    <phone>(913) 588-4565</phone>
    <email>smoon@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

